Executive Summary

Amylyx Pharmaceuticals (NASDAQ: AMLX) is an American biopharmaceutical company founded in 2013 by Justin Klee and Joshua Cohen, two former Brown University students, headquartered in Cambridge, Massachusetts. The company has lived through one of the most dramatic stories in modern biotech: after receiving FDA approval for Relyvrio in ALS (amyotrophic lateral sclerosis) in September 2022, the drug was withdrawn from the market in 2024 when the confirmatory Phase 3 trial PHOENIX showed no efficacy versus placebo. The stock lost more than 80% of its value, the company cut approximately 70% of its workforce, and many wrote it off entirely.

Instead, Amylyx made an unexpected strategic move: in July 2024, it acquired avexitide from bankrupt Eiger BioPharmaceuticals for $35.1 million; the economic package also includes asset-related obligations/royalty components disclosed in the transaction filings. Avexitide is a GLP-1 receptor antagonist (targeting the same pathway as obesity drugs like Ozempic, but with the opposite effect) and represents the most advanced candidate in the world for treating Post-Bariatric Hypoglycemia (PBH), a severe complication affecting approximately 160,000 Americans following bariatric surgery, with no approved therapy currently available.

The Phase 3 trial LUCIDITY completed enrollment in March 2026 with 78 participants, and topline data are expected in the third quarter of 2026 (July to September). If positive, Amylyx intends to file an NDA and potentially commercialize avexitide as early as 2027, with the potential advantage of becoming the first approved therapy for PBH if the benefit-risk profile is confirmed and the FDA approves the application.

From a financial standpoint, as of March 31, 2026, the company holds $279.8 million in cash, with a burn rate of approximately $37-42 million per quarter, providing a runway estimated through 2028. The pipeline also includes AMX0035 for Wolfram syndrome (Phase 2 HELIOS, positive results at 24 and 48 weeks) and AMX0114 for ALS (Phase 1 LUMINA, Cohort 2 fully enrolled as of March 2026).

This report explains in detail the biological mechanism behind PBH, how avexitide interrupts it, what the available clinical data show, and what the catalysts, risks and scenarios are for 2026-2027. Disclaimer: this content is purely informational and does not constitute investment advice.

Why Is This Drug Connected to Obesity? The Bariatric Surgery and PBH Story

This is the question that deserves a thorough answer, because at first glance it seems strange: a company fighting complications of obesity has developed a drug that blocks GLP-1, the same protein that makes drugs like Ozempic and Wegovy effective. The paradox is only apparent, and understanding it is fundamental to grasping the value of avexitide.

The Obesity Epidemic and Bariatric Surgery

Obesity is now considered a global pandemic. In the United States, more than 40% of the adult population is obese, with even higher rates in certain age groups. The metabolic consequences — type 2 diabetes, cardiovascular disease, sleep apnea, certain cancers — represent an enormous health and mortality burden. For patients with severe obesity (BMI above 35-40), diet and exercise alone are often insufficient, and even GLP-1 drugs like semaglutide have limitations in long-term weight maintenance.

In this context, bariatric surgery (or metabolic surgery) has become the most effective available treatment for severe obesity. Approximately 250,000-280,000 bariatric procedures are performed each year in the United States. The global market is estimated at around $2.8 billion in 2025 and continues to grow with geographic penetration and broadening of indications.

Roux-en-Y Gastric Bypass (RYGB): the Most Effective but Also Most Metabolically Disruptive Procedure

Among the various bariatric techniques (sleeve gastrectomy, gastric bypass, gastric banding, etc.), Roux-en-Y Gastric Bypass (RYGB) is considered the gold standard for metabolic outcomes. It accounts for approximately 43.6% of all bariatric procedures in the US. The procedure consists of:

The results of RYGB are often spectacular: 60-80% excess weight loss, type 2 diabetes remission in 50-80% of cases, improvement in blood pressure, lipid profile and quality of life. But there is a consequence that average patients are not always adequately informed about: in a significant subset of patients, these same anatomical modifications create a new and dangerous problem.

The Paradox: Surgery That Cures Obesity Can Cause Severe Hypoglycemia

After RYGB, food passes from the stomach to the intestine much more rapidly than normal (a phenomenon also called dumping syndrome). This causes the enteroendocrine L-cells of the distal small intestine to be massively stimulated and to produce levels of GLP-1 that are 3 to 10 times higher than pre-surgical baseline. GLP-1 is the hormone that signals the pancreas to produce insulin. When GLP-1 rises so dramatically, pancreatic beta cells respond with massive insulin secretion.

In a non-operated individual, this mechanism is finely regulated. But after RYGB, the response is disproportionate: the amount of insulin produced is excessive relative to the amount of glucose available. The result is a crash in blood sugar (hypoglycemia) 1-3 hours after meals, typically in the afternoon or evening hours. This is Post-Bariatric Hypoglycemia.

What Is PBH: The Complication Nobody Treats

Post-Bariatric Hypoglycemia (PBH) is a serious metabolic condition that typically develops 1-3 years after RYGB surgery. It is fundamentally the opposite of what one would expect: after a procedure designed to combat the metabolic excess associated with obesity, the patient finds themselves with excessive insulin production that drops blood sugar to dangerous levels.

The Pathophysiology: Why It Happens

After RYGB, food transits from the stomach to the intestine much more rapidly than normal. This causes the L-cells of the distal small intestine to be massively stimulated, producing GLP-1 levels 3 to 10 times higher than pre-surgical values. GLP-1 is the hormone that signals the pancreas to produce insulin. When GLP-1 surges this dramatically, pancreatic beta cells respond with massive insulin secretion.

In a non-operated subject, this mechanism is finely regulated. But after RYGB, the response is disproportionate: the insulin produced is excessive relative to the glucose available. The result is a post-prandial blood glucose crash in the 1-3 hours after meals, typically in the afternoon or evening.

Severity Classification

• Level 1 (alert): blood glucose below 70 mg/dL but above 54 mg/dL. Symptoms include tremor, sweating, palpitations. Patient can self-manage.
• Level 2 (clinically significant): glucose below 54 mg/dL. Severe hypoglycemia requiring immediate intervention with fast-acting carbohydrates. Can cause confusion and cognitive difficulty.
• Level 3 (severe, with neuroglycopenia): hypoglycemia severe enough to impair cognitive function, requiring assistance from another person. Can manifest as loss of consciousness, seizures, falls with physical injury, motor vehicle accidents.

PBH is not a minor clinical curiosity: patients with Level 2 and 3 episodes cannot drive, face significant work restrictions, live with constant fear of fainting in public, and frequently suffer from anxiety and depression. Some return to overeating to avoid hypoglycemia, negating the benefits of surgery. The mortality rate linked to accidents caused by severe PBH episodes is not negligible.

How Many People Are Affected

PBH is estimated to affect approximately 8-10% of RYGB patients. With approximately 250,000-280,000 bariatric procedures per year in the US (with RYGB accounting for about 43% of these), this translates to at least 8,000-12,000 new cases per year. The total of patients living with PBH in the US is estimated at approximately 160,000 people. There are no drugs specifically approved for this condition. All current options are off-label and often inadequate or burdened by significant side effects.

Current Treatments: All Inadequate

Physicians currently manage PBH with a collection of stopgap strategies. Octreotide requires multiple subcutaneous injections daily or continuous pump delivery, causes gallstones and GI side effects, and costs $5,000-10,000 per month off-label. Pasireotide causes paradoxical hyperglycemia in many patients. Dietary restriction is partially effective but dramatically limiting for quality of life and fails in severe cases. Revisional bariatric surgery is a last resort with uncertain outcomes and procedural risk. In this landscape of complete therapeutic scarcity, avexitide proposes a causal solution: rather than managing hypoglycemia after it occurs, it blocks the pathological mechanism at its root by interrupting GLP-1 overstimulation.

Avexitide: the Mechanism of Action Explained

Avexitide (INN: avexitide; formerly known as exendin 9-39) is a 31-amino acid peptide derived from exendin-4, a protein extracted from the saliva of the Gila monster lizard (Heloderma suspectum). While the original exendin-4 is a GLP-1 receptor agonist (like the diabetes drug exenatide, or its derivatives such as semaglutide), avexitide is structurally modified to act as a competitive antagonist of the same receptor. In practice, it binds to the GLP-1 receptor without activating it, physically blocking access for endogenous GLP-1.

Why Block GLP-1 in This Specific Context

This might seem counterintuitive: GLP-1 agonist drugs (Ozempic, Wegovy, Mounjaro) are among the most important drugs in modern medicine for diabetes and obesity management. Why would anyone want to block GLP-1?

The answer lies in the specificity of the condition: in PBH patients, GLP-1 is not deficient — it is abnormally overproduced after every meal. Post-prandial GLP-1 concentration in these patients is 3 to 10 times higher than normal values. Selectively blocking this signaling, during the post-prandial periods when it is excessive, allows reduction of the abnormal insulin secretion without interfering with GLP-1’s other beneficial effects.

Avexitide is administered subcutaneously. In the formulation studied in the LUCIDITY trial, it is given once daily (QD) at a dose of 90 mg. Its short half-life and favorable safety profile, documented across five prior clinical studies conducted by Eiger and academic researchers, are key elements for long-term tolerability.

Pre-Existing Clinical Data: Five Studies Before LUCIDITY

Avexitide is not a new molecule: it has been studied clinically for years, first by academic groups and then by Eiger BioPharmaceuticals (before the latter went bankrupt). When Amylyx acquired the asset, it had access to a robust package of safety data and proof-of-concept:

• Phase 1 and 2 (initial studies): safety and pharmacokinetics established. Avexitide demonstrated a favorable safety profile, without significant cardiac or hepatic signals.
• Phase 2b (key study pre-LUCIDITY): randomized, double-blind vs. placebo study in PBH patients after RYGB. At the 90 mg QD dose, avexitide reduced composite Level 2+3 hypoglycemic events by 64% (LS mean reduction) versus placebo. A clinically very meaningful result for a disease with no treatments.
• Studies in congenital hyperinsulinism (HI): avexitide has also demonstrated efficacy in congenital hyperinsulinism, a rare pediatric disease with a similar mechanism (genetic excess insulin). In this indication it also received Breakthrough Therapy Designation from the FDA.

FDA Designations: A Double Recognition

Avexitide holds multiple FDA regulatory designations, each relevant but important to describe precisely:

• Breakthrough Therapy Designation (BTD) for PBH: granted by the FDA when preliminary data show a drug may offer substantial improvement over existing therapies for a serious disease. The BTD ensures more frequent and structured FDA interactions during development and an expedited review pathway.
• Breakthrough Therapy Designation also for congenital hyperinsulinism (HI): in addition to PBH, Amylyx reports FDA BTD for congenital HI.
• Rare Pediatric Disease Designation in congenital HI: a designation tied to the rare pediatric nature of that indication.
• Orphan Drug Designation for hyperinsulinemic hypoglycemia: Amylyx states that this designation includes both PBH and congenital HI. ODD can provide regulatory incentives and potential post-approval market exclusivity, but it does not guarantee approval or commercial reimbursement.

The LUCIDITY Phase 3 Trial: The Binary Event of 2026

LUCIDITY is the name of the Phase 3 randomized, double-blind, placebo-controlled, multicenter trial that Amylyx is conducting for avexitide in PBH. It is the primary catalytic event for the entire AMLX investment thesis in 2026.

Trial Structure

• ClinicalTrials.gov ID: NCT06747468
• Phase: Phase 3
• Population: adults with documented post-bariatric hypoglycemia following RYGB surgery
• Participants enrolled: 78 (enrollment completed March 2026)
• Treatment duration: 16-week double-blind period
• Design: randomized, double-blind, placebo-controlled, 3:2 randomization to avexitide 90 mg once daily subcutaneously or placebo
• Setting: 21 U.S. sites according to Q1 2026 company disclosure
• Open-label extension: 32 weeks for participants completing the double-blind period
• Expanded Access Program: active in the US for patients who request it

Primary Endpoint: FDA-Agreed

One of the most reassuring aspects of LUCIDITY is that the primary endpoint was agreed with the FDA in advance, within the framework of the dialogue facilitated by Breakthrough Therapy Designation. This reduces the risk of post-trial regulatory disputes over success criteria. The primary endpoint is the reduction in composite Level 2 and Level 3 hypoglycemic events (glucose below 54 mg/dL or severe neuroglycopenia) at Week 16 versus baseline. This endpoint has direct and obvious clinical relevance: fewer severe hypoglycemia episodes equals less risk for the patient. It is not a surrogate endpoint that is difficult to interpret.

Why 78 Patients May Be Sufficient

A sample of 78 participants might seem small for a pivotal trial. But two factors must be considered. First, this is a rare and orphan disease, where the FDA and EMA traditionally accept smaller studies provided the design is rigorous and the treatment effect is clinically significant. Second, Phase 2b data showed a 64% reduction in composite events — an effect of such magnitude that it translates into very high statistical power even with a sample of 78 people. The sample size was calculated precisely based on this effect size.

Timeline and Next Steps

With enrollment completed in March 2026, the 16-week follow-up period concludes presumably by June-July 2026. Statistical analysis, data cleaning and topline report preparation typically require 6-10 weeks. This suggests topline data in the July-September 2026 period, which Amylyx has communicated as “Q3 2026”. If results are positive:

1. NDA submission to the FDA: likely Q4 2026 or Q1 2027
2. FDA review timeline: 10-12 months standard; 6-8 months with Priority Review (possible given the BTD)
3. Potential approval and commercial launch: 2027

Full Pipeline: Beyond Avexitide

Amylyx is not a single-product company. Its pipeline includes three assets at different clinical stages, each with a distinct scientific rationale and the potential to add independent value beyond the avexitide/PBH story.

AMX0035 — Wolfram Syndrome (HELIOS Phase 2)

Wolfram syndrome (also known as DIDMOAD: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness) is an extremely rare autosomal recessive genetic disease caused by mutations in the WFS1 gene. It is a progressive neurodegenerative disease affecting the hypothalamus, cerebellum, optic nerve and pancreas, typically onset in childhood with an inexorably progressive course. No approved treatments exist. AMX0035 is the same molecular formulation as Relyvrio (sodium phenylbutyrate + taurursodiol, TURSO), but in this indication the context is entirely different: not a rare adult neurodegenerative disease with a single pivotal study, but an ultra-rare pediatric condition where the drug can act on the endoplasmic reticulum stress and mitochondrial stress pathways underlying the pathology. The mechanistic rationale is solid and distinct from that in ALS. The HELIOS Phase 2 trial produced positive data at both 24 and 48 weeks. Amylyx has indicated that additional longer-term HELIOS data are expected to be presented at an upcoming scientific meeting, while any pivotal path would depend on FDA alignment.

AMX0114 — ALS (LUMINA Phase 1)

AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2, a biological target implicated in ALS pathogenesis. Critically, this is a completely different asset from Relyvrio: not an attempt to replace the failed drug, but a molecule with a different mechanism of action, different molecular target, and potentially different patient population. The Phase 1 LUMINA trial is a dose-escalation study evaluating safety, pharmacokinetics, and preliminary efficacy biomarkers (neurofilament light chain). Cohort 2 completed enrollment in March 2026. Cohort 1 biomarker data were expected at the ENCALS conference in June 2026.

Financial Position

Amylyx’s financial profile is one of the most reassuring aspects of the story: after the dramatic 2024 restructuring, the company entered 2025-2026 with a robust cash position and a rightsized cost structure.

Cash and Runway

As of March 31, 2026, Amylyx holds $279.8 million in cash and short-term investments (versus $317 million at December 31, 2025). Cash consumption in Q1 2026 was approximately $37.2 million. At the current spending pace, the company has a cash runway estimated through 2028, comfortably sufficient to cover LUCIDITY topline data, a potential NDA submission, and part of the FDA review period. No near-term capital raise is necessary to reach the primary catalyst.

Avexitide Acquisition: A Bankruptcy Bargain

The quality of the avexitide acquisition from Eiger in July 2024 deserves emphasis: $35.1 million for an asset with Breakthrough Therapy Designation, five clinical studies (including a Phase 2b with 64% reduction in primary endpoints), and a complete data package. Eiger was in bankruptcy and had to sell. Amylyx acquired a potentially multi-hundred-million-dollar asset for slightly more than it would cost to run a single Phase 2 from scratch. The asset-related royalty/obligation structure remains a cost to include in any commercial model, but it does not change the central point: Amylyx acquired a Phase 3-ready program at a modest upfront price relative to the cost of rebuilding a comparable clinical package from scratch.

Dilution Considerations

With approximately 110.6 million weighted-average basic and diluted shares used in Q1 2026 loss-per-share calculations and $279.8 million in cash and short-term investments, indicative cash per share is approximately $2.53. The filings show a relatively clean balance-sheet structure, with total liabilities limited relative to the cash position. Near-term dilution risk is low, but will increase in the pre-commercial and launch phase if LUCIDITY data are positive: it is standard for biotechs approaching the market to raise additional capital (often under favorable conditions following a positive catalyst) to fund the commercial infrastructure buildout.

Management

Amylyx is led by its co-founders, an unusual co-leadership structure that has characterized the company since its founding.

• Justin Klee (Co-CEO): co-founded Amylyx in 2013 at Brown University with Joshua Cohen, both then undergraduates. Led Relyvrio’s development from university research to FDA approval in 2022, one of the fastest success stories in biotech history. After Relyvrio’s failure, orchestrated the restructuring and strategic pivot to avexitide.
• Joshua Cohen (Co-CEO): co-founder with the same university background. Overseen scientific development and regulatory affairs. Together, Klee and Cohen built the company from scratch and maintained leadership through the most difficult moments, including the voluntary withdrawal of Relyvrio from the market — a decision that ultimately strengthened management credibility with the FDA and long-term institutional investors.

The co-CEO structure is often perceived externally as a potential governance weakness, but in Amylyx’s case the two founders have demonstrated cohesion and shared vision, even in difficult decisions. The workforce has been reduced from over 600 employees during the commercial period to approximately 170-180, creating a leaner R&D-focused organization.

Catalyst Timeline 2024–2027

• July 2024Acquisition of avexitide from bankrupt Eiger BioPharmaceuticals for $35.1M. Strategic pivot toward PBH and rare metabolic diseases.
• Late 2024LUCIDITY Phase 3 enrollment initiation and Expanded Access Program launch for avexitide.
• Q1 2025HELIOS Week 24 data (AMX0035 Wolfram) presented — positive results.
• H2 2025HELIOS Week 48 data (AMX0035 Wolfram) — positive, trial continues.
• March 2026LUCIDITY enrollment completed (78 participants). LUMINA Cohort 2 (AMX0114 ALS) fully enrolled.
• June 2026ENCALS: AMX0114 Cohort 1 biomarker data. Exploratory, early-stage data.
• Q3 2026 — MAINLUCIDITY topline data: the main event of the year for AMLX. L2+L3 hypoglycemic event reduction at 16 weeks vs. placebo.
• 2026 / next scientific updateHELIOS longer-term data (AMX0035 Wolfram): Amylyx has indicated additional longer-term data will be presented at an upcoming scientific meeting; the regulatory direction will depend on FDA alignment.
• Q4 2026 – Q1 2027If LUCIDITY positive: potential NDA submission for avexitide (PBH). BTD supports accelerated FDA dialogue.
• 2027If NDA accepted with Priority Review: potential FDA approval and commercial launch of avexitide. First-ever approved drug for PBH worldwide.

Competitive Landscape: An Empty Market

One of the most compelling aspects of the avexitide story is the complete absence of approved pharmacological competition. PBH is a de facto orphan indication: no drugs carry a specific label for this condition. This creates a potentially very strong first-mover advantage.

All current physician options for managing PBH patients are off-label. Octreotide requires multiple subcutaneous injections or continuous pump delivery, causes gallstones and GI side effects, and costs $5,000-10,000 per month. Pasireotide paradoxically causes hyperglycemia in many patients. Dietary restriction is partially effective but quality-of-life limiting and ineffective in severe cases. As of June 2026, avexitide appears to be the most advanced PBH-specific candidate in clinical development, and LUCIDITY is the key pivotal Phase 3 program to watch. No other PBH-specific candidate appears comparably close to a pivotal readout based on currently visible trial registries and company disclosures. The combination of no approved drug + no Phase 3 competitor + Breakthrough Therapy Designation creates a potentially very significant regulatory and commercial opportunity window.

The GLP-1 Paradox: A Sword That Cuts Both Ways in the Ozempic Era

There is an important narrative element to consider: the explosion of GLP-1 agonist drugs for obesity and diabetes (semaglutide, tirzepatide, etc.) is driving a strong increase in bariatric procedures both as an alternative and as a complement to these drugs in more severely obese patients. This means the number of potential PBH patients is set to increase over the long term, not decrease. The irony is that the same GLP-1 mechanism underlying the world’s most famous anti-obesity drugs is what avexitide aims to counteract in a specific post-surgical population. It is a niche, but a growing niche.

Possible Scenarios for Q3 2026 and Beyond

LUCIDITY is a high-impact binary event. Thinking in terms of scenarios is useful, keeping in mind that reality often falls in between.

The scenarios described here are hypothetical analytical exercises. They do not constitute investment recommendations.

Key Risk Factors

• Clinical trial risk (LUCIDITY): failure is always possible in any Phase 3. The inherent variability in PBH episode frequency, the difficulty of accurately measuring nocturnal events (some are asymptomatic), and inter-site variability can influence the outcome. The 78-patient sample provides sufficient statistical power if the treatment effect is large, but is vulnerable to high variance or a more modest effect size than expected from Phase 2b data.
• Regulatory risk: even with positive data, the FDA may request additional studies, impose label conditions, or issue a Complete Response Letter (CRL) for manufacturing or safety reasons. The BTD reduces but does not eliminate this risk.
• Commercial execution risk: if approved, Amylyx would need to build or orchestrate (through licensing or partnership) a commercial capability targeting PBH. PBH diagnosis is often delayed or missed in routine clinical practice, requiring significant investment in disease awareness among general practitioners, endocrinologists and bariatric surgeons.
• Pricing and access risk: US payers (insurance companies, PBMs) are increasingly restrictive on orphan drugs. The price of avexitide and reimbursement policies are critical unknowns for real commercial potential.
• Future dilution risk: if approved, capital will be needed for commercial launch. If failed, capital will be needed to sustain the pipeline. In both cases, future dilution is probable.
• Track record risk: Relyvrio’s failure has left a mark on market psychology. Many investors will remember the pattern of “approval, enthusiasm, confirmatory trial failure.” This may make it difficult for the stock to express full valuation even with positive LUCIDITY data, at least initially.
• Data provenance risk: avexitide comes from a bankrupt company. While the data package is rich and the molecule is well-characterized, a critical buyer might raise questions about the quality of pre-existing data generated by Eiger and academic researchers.